News

Latest updates.

Publications, clinical milestones and company announcements from Atrogi.

All news

Company news and publications.

Press release

Atrogi announces first subjects dosed in human trial for lead candidate ATR-258

Atrogi’s breakthrough technology, validated by publication of landmark research in Cell in June 2025, enables, for the first time, development of next-generation, highly selective β2-agonists for chronic use

Read more
Company update

Atrogi Appoints Paul Little, PhD, as Chief Executive Officer to Accelerate Growth and Advance Next Phase

Read article
Publication

Cell Paper: GRK-biased adrenergic agonists for T2D and obesity (Motso et al.)

Motso et al. · June 2025 · Cell 188(19):5142–5156.e23

Read more
Company update

Phase I Results Presented at EASD 2024

Company update

Publication on Combatting Obesity and Metabolic Complications

Company update

Positive Phase I Clinical Data — First-in-Class Insulin-Independent Treatment

Company update

First Patient Treated in ATTRACTIVE 1 Trial

Company update

Anders Ekblom Appointed Chairman of the Board

Company update

SEK 90M Series A Completed

Company update

SEK 90 Million Rights Issue Completed

Company update

Eurostars Grant for Obesity Project

Stay up to date

News as it happens.
Follow Atrogi.

Follow Atrogi on LinkedInInvestor relations